What is Kalaris Therapeutics, Inc. (KLRS) stock price today?

Kalaris Therapeutics, Inc. (KLRS) currently trades at $5.52 per share. The stock has a market capitalization of $138.41M and a P/E ratio of —x.

Is KLRS stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Kalaris Therapeutics, Inc. has a Smart Value Score of 29/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is 4.40.

Is Kalaris Therapeutics, Inc. financially healthy?

Kalaris Therapeutics, Inc.'s Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of 4.40 places it in the safe zone.

KLRS

Kalaris Therapeutics, Inc.

NASDAQ: KLRS · HEALTHCARE · BIOTECHNOLOGY

$5.52

+0.18% today

Updated 2026-04-30

Market cap

$138.41M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.85

Dividend yield

—

52W range

$2 – $12

Volume

0.1M

Market cap

$138.41M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.85

Dividend yield

—

52W range

$2 – $12

Volume

0.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

8.5

Quality

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

4.4

Altman Z-Score

Safe zone

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$19.43

+251.99%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy4 Buy1 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Altman Z 4.40 — safe zone

+ Debt/equity 0.04x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-9.33M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-15.48M	$-14.70M	$-58.77M	$-43.44M	$-10.00M
EPS	—	—	—	—	$-2.85
Free cash flow	$-9.78M	$-14.13M	$-67.70M	$-43.18M	$-9.33M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
KLRS	$138.41M	29	4.3	3.0	5.0	8.5	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Kalaris Therapeutics, Inc. trades at $5.52. Our Smart Value Score of 29/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 4.40, it sits in the safe zone.

Frequently asked questions

What is Kalaris Therapeutics, Inc.'s stock price?

Kalaris Therapeutics, Inc. (KLRS) trades at $5.52.

Is Kalaris Therapeutics, Inc. overvalued?

Smart Value Score 29/100 (Grade F, Strong Sell).

What is the price target of Kalaris Therapeutics, Inc. (KLRS)?

The analyst target price is $19.43, representing +252.0% upside from the current price of $5.52.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

4.40 — safe zone.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

kalaristx.com

Quick metrics

P/S ratio—

ROE-308.10%

Beta—

50D MA$7.76

200D MA$6.28

Shares out0.02B

Float0.01B

Short ratio—

Avg volume0.1M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

KLRS vs LLY →KLRS vs JNJ →KLRS vs ABBV →Stock screener →